Diabetes devices are the hardware, equipment, and software used by diabetes patients to regulate blood glucose levels, prevent diabetes complications, lessen the burden of dealing with diabetes, and enhance the quality of life. Diabetes devices include blood glucose meters, continuous glucose monitors (CGMs), and insulin pumps. These devices are linked to enhanced glycemic management and decreased hypoglycemia. Historically, diabetes devices were classified into two categories: insulin administration through syringe, pen, or pump; and blood glucose monitoring via meter or continuous glucose monitor. More recently, these devices have developed to include hybrid devices that monitor glucose and dispense insulin, in some cases automatically.
Diabetes devices, when used effectively, can enhance the lives and health of people with diabetes; nevertheless, the sophistication and rapid evolution of the technology environment can be a hurdle to patient and provider adoption. The market is driven primarily by factors like an increase in technical improvements and a rise in the prevalence of obesity. In addition, the increasing acceptance of insulin delivery devices and the majority of diabetes are boosting market expansion.
The increasing incidences of diabetes due to age, obesity, and a sedentary lifestyle is one of the primary factors driving the growth of the diabetes devices market. Diabetes is substantially influenced by obesity. As reported by the WHO, in 2016, over 1.9 billion adults were overweight, and around 650 million were obese. Risk factors like smoking, obesity and high cholesterol are anticipated to increase the prevalence of diabetes, driving the demand for diabetes devices. The increased number of activities conducted by governments and non-profit groups to raise awareness of diabetes is also anticipated to promote the adoption of diabetes devices.
For instance, the m-Diabetes mobile health project was established by the Ministry of Health and Family Welfare, the WHO Country Office of India, and other partners. This health effort aimed to raise awareness about early diabetes diagnosis and treatment. Similarly, the WHO and IDF collaborated to combat and prevent diabetes and ensure a high quality of life for people worldwide. The WHO Diabetes Program also aims to prevent type 2 diabetes, reduce complications, and improve the quality of life for people with diabetes. To increase diabetes prevention and control, NGOs and governments are developing norms and standards, raising knowledge about diabetes prevention, and encouraging surveillance. Consequently, an increase in awareness initiatives is anticipated to aid in diagnosing diabetes, thereby increasing the use of diabetes devices.
Medtronic is a diversified medical device company that develops and markets products for various clinical areas, including cardiovascular diseases, cardiac rhythm disorders, urological and digestive disorders, spinal conditions and musculoskeletal trauma, neurological disorders, diabetes, ear, nose, and throat conditions. The corporation owns research, manufacturing, and sales facilities and training centers worldwide. The two critical segments of Medtronic are the heart and vascular division and the rehabilitative therapies group. Its cardiac and vascular division comprises three business segments: coronary and peripheral, endovascular, and structural heart. Its range of restorative therapies has four divisions: spinal, neuromodulation, diabetes, and surgical technologies.
In 2022, Medtronic and DaVita Inc. announced the intent to launch a new, independent medical device firm specializing in renal care, "NewCo," to improve the patient treatment experience and overall outcomes.
Abbott Laboratories is a global American medical equipment and health care corporation headquartered in Abbott Park, United States. The company was formed in 1888 to manufacture well-known medications; today, it sells medical gadgets, diagnostics, branded generic pharmaceuticals, and nutritional items. Abbott's major business segments are pharmaceuticals, medical devices, nutrition, and diagnostics. The corporation has research, production, sales, and distribution operations in more than 150 countries. Abbott India Limited, a subsidiary of the company established in India for over a century, is currently India's leading healthcare products manufacturer.
In 2022, Abbott announced the development of a new bio-wearable sensor that would monitor glucose and ketone levels continually.
Bayer AG is the parent company of Bayer Healthcare AG. Ascensia Diabetes Care Holdings began operations in January 2016 after Panasonic Healthcare Holdings bought the diabetes care division of Bayer AG. Ascensia Diabetes Care is a global corporation devoted to improving the health and lifestyles of people living with diabetes. Ascensia Diabetes Care is built on more than seven decades of offering new products and solutions that have a beneficial impact on people with diabetes.
In 2022, Ascensia Diabetes Care Holdings AG announced the new Eversense PASS savings program and the Eversense® E3 Continuous Glucose Monitoring (CGM) System for patients in the United States.
Dexcom, Inc. is the premier supplier of Continuous Glucose Monitoring (CGM) devices used to evaluate and administer diabetic therapy. The company focuses on improving results for caregivers, physicians, and patients by providing innovative solutions and technology for diabetes treatment. Dexcom Inc. designs, develops, manufactures, and sells continuous glucose monitoring (CGM) devices utilized by individuals with diabetes and healthcare professionals in hospitals. The company's essential products include the integrated Dexcom G6 CGM system, the Dexcom Share remote monitoring system, the related software, and mobile applications.
In 2022, Dexcom, Inc launched the latest Dexcom ONE Continuous Glucose Monitoring System in the United Kingdom. The Dexcom ONE system is a real-time CGM (rt-CGM) that is simple to use and will be more inexpensive and accessible to patients with diabetes.
Hoffmann-La Roche Ltd. is a manufacturer of medical devices headquartered in Switzerland. Pharmaceuticals and diagnostics are the two primary business divisions of the corporation. Roche Professional Diagnostics, Roche Molecular Diagnostics, Roche Tissue Diagnostics, and Roche Diabetes Care make up Roche Diagnostics. It operates in four segments: diabetic care, specialist diagnostics, tissue diagnostics, and molecular diagnostics. Roche Diagnostics has a global presence in about 158 nations. The company serves clinicians, scholars, laboratories, hospitals, patients, and blood banks with its products.
In 2022, F. Hoffmann-La Roche Ltd. released the Elecsys® HCV Duo immunoassay in nations that recognize the CE Mark. Elecsysâ HCV Duo is the first immunoassay that permits the simultaneous and independent assessment of hepatitis C virus (HCV) antigen and antibody status from a single plasma or blood sample from a human.
Sanofi S.A. is a multinational French pharmaceutical and healthcare corporation with its headquarters in Paris, France. Initially founded in 1973, the company joined Synthélabo in 1999 to form Sanofi-Synthélabo. Sanofi is a multinational healthcare company with five global business units: Sanofi Pasteur (Vaccines), Consumer Healthcare, General Medicine & Emerging Markets, Sanofi Genzyme (Specialty Care), and Diabetes & Cardiovascular. The company offers health services in more than 170 countries and operates 75 manufacturing facilities in 33 countries. Sanofi conducts research and development, manufactures, and markets pharmaceutical products primarily for the prescription market but also produces over-the-counter drugs.
In 2022, Sanofi Global Health launched Impact®, a new brand of Sanofi's standard of care medications created specifically for charitable distribution to at-risk communities in the world's poorest nations.
Novo Nordisk A/S is a Danish global pharmaceutical corporation with production sites in eight countries and subsidiaries or offices in five. Novo Nordisk develops and promotes pharmaceutical products and services, including drugs and devices for the treatment of diabetes. In addition to its involvement in hemostasis management, growth hormone therapy, and hormone replacement therapy, Novo Nordisk is also involved in the direction of hemostasis. Novo Nordisk A/S provides goods and services for controlling diabetes, hemostasis, growth hormone, and hormone replacement. The company's research and innovation facilities are located in several countries, including Denmark, China, India, and the United States, on three continents. Products are distributed in more than 180 nations worldwide.
In 2022, Novo Nordisk A/S and Echosens announced an alliance to enhance non-alcoholic steatohepatitis (NASH) early diagnosis and raise knowledge of the condition among patients, healthcare professionals, and other stakeholders.
Insulet Corporation is an advanced medical device manufacturer that develops cutting-edge diabetes control products. The company facilitates diabetes treatment with its OmniPod product platform. Its global distribution network spans roughly 13 nations. The Omnipod® Insulin Management System offers an innovative replacement for conventional insulin delivery techniques. The disposable Pod's straightforward, wearable design allows for up to three days of continuous insulin delivery without having to see or touch a needle. Insulet additionally takes advantage of the distinctive features of its Pod by customizing the Omnipod technology platform for the administration of non-insulin subcutaneous medications in a variety of therapeutic settings.
In 2022, Insulet Corporation launched the Omnipodâ 5 Automated Insulin Delivery System across the US retail pharmacy channels.
In 2003, Ypsomed was formed following a break from the Burgdofer Disetronic Group. The company specializes in designing and producing medical devices and instruments for diagnosing and treating diabetes, growth problems, and infertility, among other conditions. As a specialist in innovation and technology, it is the partner of choice of pharmaceutical and biotech firms for manufacturing autoinjectors, pens, and pump systems to administer liquid pharmaceuticals. Ypsomed distributes and promotes its product offerings under the umbrella brands MyLife Diabetes care straight to patients or pharmacies and hospitals and under YDS Ypsomed Delivery Systems in business-to-business activities with pharmaceutical firms. The company has collaborated with various manufacturers, including Sanofi-Aventis, Eli Lilly, Pfizer, Roche, Genentech, Merck Serono, Amylin, NPS, etc. It has numerous production facilities throughout Switzerland and a broad distribution network.
In 2022, Ypsomed, Abbott, and CamDiab allied to create and market an integrated automated insulin delivery (AID) system to enable persons with diabetes to cope with the stress of constant diabetes control. The partnership's initial focus will be on nations throughout Europe.
Valeritas is a medical technology business dedicated to discovering and commercializing new medication delivery methods that contribute to clinical and humanistic results for patients, with an initial emphasis on diabetes management. Valeritas, Inc. is a medical equipment manufacturer and distributor specializing in medication delivery solutions. In April 2020, the enterprise was obtained by Zealand Pharma A.S. Valeritas created V-GO, a disposable insulin pump, and a microneedle patch for Type 2 diabetes treatment.